Institution Directory

Clinical trials at Children's Hospital of Philadelphia

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

600

Shown on this page

Current sort

Live official records

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obstructive Sleep Apnea (OSA), Down Syndrome
Interventions: ato-oxy, Oxygen; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 6 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Tucson, Arizona • San Diego, California • Miami, Florida + 2 more

Conditions: Congenital Central Hypoventilation Syndrome, Congenital Central Hypoventilation, CCHS, CCHS With Hirschsprung Disease, CCHS With Neural Crest Tumor, CCHS With Neuroblastoma
Interventions: NIH Toolbox Cognition Battery; Other
Lead sponsor: Ilya Khaytin; Other
Eligibility: 3 Years to 85 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2035
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more

Conditions: Brain Injury Traumatic Mild, Brain Injuries, Brain Injuries, Acute, Head Injury With Intracranial Hemorrhage, Head Injury Trauma, Brain Injury Traumatic Focal With Loss of Consciousness, Skull Fractures, Diffuse Axonal Injury, Intracranial Hemorrhages, Head Injury
Interventions: Validated Questionnaires, Questionnaires, Clinician / Medical Record Variables; Behavioral · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 11 Years to 17 Years
Enrollment: 2,592 participants
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Sacramento, California • Philadelphia, Pennsylvania • Providence, Rhode Island + 3 more

Conditions: Cardiomyopathy
Interventions: Not listed
Lead sponsor: Tenaya Therapeutics; Industry
Eligibility: 0 Years to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 17 more

Conditions: Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
Interventions: Lurbinectedin; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 10 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 6
States / cities: Los Angeles, California • Iowa City, Iowa • Boston, Massachusetts + 3 more

Conditions: Chronic Pain
Interventions: Supportive Parenting for Anxious Childhood Emotions - Pain; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 10 Years to 17 Years
Enrollment: 39 participants
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Palo Alto, California • Philadelphia, Pennsylvania

Conditions: Syphilis, Congenital
Interventions: Benzathine Penicillin, Amoxicillin; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 0 Days to 30 Days
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 11
States / cities: Birmingham, Alabama • Mobile, Alabama • Orange, California + 8 more

Conditions: Friedreich Ataxia
Interventions: Not listed
Lead sponsor: Friedreich's Ataxia Research Alliance; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2048
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Gainesville, Florida + 6 more

Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Interventions: 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate; Radiation · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 211
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more

Conditions: Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma, T Lymphoblastic Lymphoma
Interventions: AKR1C3-activated Prodrug AST-3424, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography; Drug · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 12 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 163
States / cities: Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 94 more

Conditions: High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
Interventions: Olutasidenib + TMZ; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 12 Years to 39 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 11
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 8 more

About this Children's Hospital of Philadelphia institution page

What this page lists: ClinicalTrials.gov records that list Children's Hospital of Philadelphia in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Children's Hospital of Philadelphia

Filter and sort this campus

Live official records

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

Endotype DIrected Treatment for OSA in Down Syndrome

Neurocognition in Congenital Central Hypoventilation Syndrome (CCHS)

Screening Emotions in Adolescents at the Hospital for mTBI

Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

Lurbinectedin in FET-Fused Tumors

SPACE for Youth With Chronic Pain

Congenital Syphilis Treatment Trial (CONSISTENT) in Neonates

Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

Study of Olutasidenib and Temozolomide in HGG

About this Children's Hospital of Philadelphia institution page